

Asia Pacific Pharmaceutical Manufacturing Industry 2022-2032 by Formulation, Route of Administration, Consumer Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity

<https://marketpublishers.com/r/A698267F4955EN.html>

Date: December 2023

Pages: 168

Price: US\$ 2,210.00 (Single User License)

ID: A698267F4955EN

Abstracts

Asia Pacific pharmaceutical manufacturing industry market will grow by 11.3% annually with a total addressable market cap of \$57.26 billion over 2023-2032. The growth is driven by the increased drug approvals, increasing prevalence of chronic ailments, growing geriatric population, high R&D investment in pharmaceutical industry, increasing per capita healthcare expenditure, and technological advancements in manufacturing processes.

Highlighted with 90 tables and 69 figures, this 168-page report “Asia Pacific Pharmaceutical Manufacturing Industry 2022-2032 by Formulation, Route of Administration, Consumer Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific pharmaceutical manufacturing industry market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2020-2022 and provides forecast from 2023 till 2032 with 2022 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

Market Structure

Growth Drivers

Restraints and Challenges

Emerging Product Trends & Market Opportunities

Porter's Fiver Forces

The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Asia Pacific pharmaceutical manufacturing industry market in every aspect of the classification from perspectives of Formulation, Route of Administration, Consumer Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country.

Based on Formulation, the Asia Pacific market is segmented into the following sub-markets with annual revenue (\$ mn) for 2022-2032 included in each section.

Tablets

Capsules

Injectable

Sprays

Suspensions

Powders

Other Formulations

Based on Route of Administration, the Asia Pacific market is segmented into the following sub-markets with annual revenue (\$ mn) for 2022-2032 included in each section.

Oral Medicine

Topical Medicine

Parenteral Medicine

Inhalations

Other Routes of Administration

By Consumer Group, the Asia Pacific market is segmented into the following sub-markets with annual revenue (\$ mn) for 2022-2032 included in each section.

Children & Adolescents (17 years old and below)

Adults (18-64 years old)

Geriatric (65 years old and above)

By Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue (\$ mn) for 2022-2032 included in each section.

Cardiovascular Diseases

Pain

Diabetes

Cancer

Respiratory Diseases

Neurological Diseases

Orthopedics

Other Applications

By Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue (\$ mn) for 2022-2032 included in each section.

Branded Prescription Drugs

Generic Prescription Drugs

OTC Drugs

By Distribution Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue (\$ mn) for 2022-2032 included in each section.

Retail Channels

Non-retail Channels

By Manufacturing Facility, the Asia Pacific market is segmented into the following sub-markets with annual revenue (\$ mn) for 2022-2032 included in each section.

In-house Facility

Outsourced Facility

Geographically, the following national/local markets are fully investigated:

Japan

China

South Korea

Australia

India

Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)

For each key country, detailed analysis and data for annual revenue (\$ mn) are available for 2022-2032. The breakdown of national markets by Formulation, Route of Administration, and Drug Type over the forecast years are also included.

The report also covers the current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Selected Key Players:

Abbott Laboratories

Aenova Group

Amgen Inc.

AstraZeneca

Catalent Inc.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences Inc.

GlaxoSmithKline plc

Johnson & Johnson

Lonza Group

Lupin Limited

Merck & Co., Inc.

Novartis AG

Novo Nordisk

Patheon Inc.

Pfizer CentreSource

Sanofi SA

Takeda

(Please note: The report will be updated before delivery so that the latest historical year is the base year, and the forecast covers at least 5 years over the base year.)

Contents

1 INTRODUCTION

- 1.1 Industry Definition and Research Scope
 - 1.1.1 Industry Definition
 - 1.1.2 Research Scope
- 1.2 Research Methodology
 - 1.2.1 Overview of Market Research Methodology
 - 1.2.2 Market Assumption
 - 1.2.3 Secondary Data
 - 1.2.4 Primary Data
 - 1.2.5 Data Filtration and Model Design
 - 1.2.6 Market Size/Share Estimation
 - 1.2.7 Research Limitations
- 1.3 Executive Summary

2 MARKET OVERVIEW AND DYNAMICS

- 2.1 Market Size and Forecast
 - 2.1.1 Impact of COVID-19 on World Economy
 - 2.1.2 Impact of COVID-19 on the Market
 - 2.1.3 Impact of Russia-Ukraine Conflict: War Slows Economic Recovery
- 2.2 Major Growth Drivers
- 2.3 Market Restraints and Challenges
- 2.4 Emerging Opportunities and Market Trends
- 2.5 Porter's Fiver Forces Analysis

3 SEGMENTATION OF ASIA PACIFIC MARKET BY FORMULATION

- 3.1 Market Overview by Formulation
- 3.2 Tablets
- 3.3 Capsules
- 3.4 Injectable
- 3.5 Sprays
- 3.6 Suspensions
- 3.7 Powders
- 3.8 Other Formulations

4 SEGMENTATION OF ASIA PACIFIC MARKET BY ROUTE OF ADMINISTRATION

- 4.1 Market Overview by Route of Administration
- 4.2 Oral Medicine
- 4.3 Topical Medicine
- 4.4 Parenteral Medicine
- 4.5 Inhalations
- 4.6 Other Routes of Administration

5 SEGMENTATION OF ASIA PACIFIC MARKET BY CONSUMER GROUP

- 5.1 Market Overview by Consumer Group
- 5.2 Children & Adolescents (17 years old and below)
- 5.3 Adults (18-64 years old)
- 5.4 Geriatric (65 years old and above)

6 SEGMENTATION OF ASIA PACIFIC MARKET BY THERAPEUTIC APPLICATION

- 6.1 Market Overview by Therapeutic Application
- 6.2 Cardiovascular Diseases
- 6.3 Pain
- 6.4 Diabetes
- 6.5 Cancer
- 6.6 Respiratory Diseases
- 6.7 Neurological Diseases
- 6.8 Orthopedics
- 6.9 Other Applications

7 SEGMENTATION OF ASIA PACIFIC MARKET BY DRUG TYPE

- 7.1 Market Overview by Drug Type
- 7.2 Branded Prescription Drugs
- 7.3 Generic Prescription Drugs
- 7.4 OTC Drugs

8 SEGMENTATION OF ASIA PACIFIC MARKET BY DISTRIBUTION CHANNEL

- 8.1 Market Overview by Distribution Channel
- 8.2 Retail Channels

8.3 Non-retail Channels

9 SEGMENTATION OF ASIA PACIFIC MARKET BY MANUFACTURING FACILITY

9.1 Market Overview by Manufacturing Facility

9.2 In-house Facility

9.3 Outsourced Facility

10 ASIA-PACIFIC MARKET 2022-2032 BY COUNTRY

10.1 Overview of Asia-Pacific Market

10.2 Japan

10.3 China

10.4 Australia

10.5 India

10.6 South Korea

10.7 Rest of APAC Region

11 COMPETITIVE LANDSCAPE

11.1 Overview of Key Vendors

11.2 New Product Launch, Partnership, Investment, and M&A

11.3 Company Profiles

Abbott Laboratories

Aenova Group

Amgen Inc.

AstraZeneca

Catalent Inc.

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

Gilead Sciences Inc.

GlaxoSmithKline plc

Johnson & Johnson

Lonza Group

Lupin Limited

Merck & Co., Inc.

Novartis AG

Novo Nordisk

Patheon Inc.

Pfizer CentreSource

Sanofi SA

Takeda

RELATED REPORTS

List Of Tables

LIST OF TABLES

Table 1. Snapshot of Asia Pacific Pharmaceutical Manufacturing Industry in Balanced Perspective, 2022-2032

Table 2. World Pharmaceuticals Output by Region, 2022-2025, annual percentage change

Table 3. World Economic Outlook, 2021-2031

Table 4. World Economic Outlook, 2021-2023

Table 5. Scenarios for Economic Impact of Ukraine Crisis

Table 6. World Health Spending by Region, \$ bn, 2013-2020

Table 7. Main Product Trends and Market Opportunities in Asia Pacific Pharmaceutical Manufacturing Industry

Table 8. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, \$ mn

Table 9. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, \$ mn

Table 10. Asia Pacific Pharmaceutical Manufacturing Industry by Consumer Group, 2022-2032, \$ mn

Table 11. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application, 2022-2032, \$ mn

Table 12. Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, \$ mn

Table 13. Asia Pacific Pharmaceutical Manufacturing Industry by Distribution Channel, 2022-2032, \$ mn

Table 14. Asia Pacific Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2022-2032, \$ mn

Table 15. APAC Pharmaceutical Manufacturing Industry by Country, 2022-2032, \$ mn

Table 16. Japan Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, \$ mn

Table 17. Japan Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, \$ mn

Table 18. Japan Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, \$ mn

Table 19. China Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, \$ mn

Table 20. China Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, \$ mn

Table 21. China Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, \$ mn

Table 22. Australia Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, \$ mn

Table 23. Australia Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, \$ mn

Table 24. Australia Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, \$ mn

Table 25. India Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, \$ mn

Table 26. India Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, \$ mn

Table 27. India Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, \$ mn

Table 28. South Korea Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, \$ mn

Table 29. South Korea Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, \$ mn

Table 30. South Korea Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, \$ mn

Table 31. Pharmaceutical Manufacturing Industry in Rest of APAC by Country/Region, 2022-2032, \$ mn

Table 32. Abbott Laboratories: Company Snapshot

Table 33. Abbott Laboratories: Business Segmentation

Table 34. Abbott Laboratories: Product Portfolio

Table 35. Aenova Group: Company Snapshot

Table 36. Aenova Group: Business Segmentation

Table 37. Aenova Group: Revenue by Product, 2018-2019, thousand Euro

Table 38. Aenova Group: Recent Developments

Table 39. Amgen Inc.: Company Snapshot

Table 40. Amgen Inc.: Approved Drugs or Therapeutic Biologicals

Table 41. Astrazeneca: Company Snapshot

Table 42. Catalent Inc.: Company Snapshot

Table 43. Catalent Inc.: Business Segmentation in 2018

Table 44. Catalent Inc.: Product Portfolio

Table 45. Catalent Inc.: Revenue, 2018-2020, \$ million

Table 46. Catalent Inc.: Revenue by Region in 2018

Table 47. Eli Lilly and Company: Company Snapshot

Table 48. Eli Lilly and Company: Pharmaceutical Brands

Table 49. F. Hoffmann-La Roche: Company Snapshot

- Table 50. F. Hoffmann-La Roche: Business Segmentation
- Table 51. F. Hoffmann-La Roche: Revenue, 2017-2019, \$ bn
- Table 52. Gilead Sciences: Company Snapshot
- Table 53. Gilead Sciences: Main Products
- Table 54. GlaxoSmithKline: Company Snapshot
- Table 55. GlaxoSmithKline: Business Segmentation
- Table 56. GlaxoSmithKline: Product Portfolio
- Table 57. GlaxoSmithKline: Revenue, 2018-2020, \$ bn
- Table 58. Johnson & Johnson: Company Snapshot
- Table 59. Johnson & Johnson: Business Segments
- Table 60. Lonza Group: Company Snapshot
- Table 61. Lonza Group: Business Segmentation in 2018
- Table 62. Lonza Group: Product Portfolio
- Table 63. Lonza Group: Revenue by Region in 2018
- Table 64. Lupin Limited: Company Snapshot
- Table 65. Lupin Limited: Business Segmentation
- Table 66. Merck & Co., Inc.: Company Snapshot
- Table 67. Merck & Co., Inc.: Business Segmentation
- Table 68. Merck & Co., Inc.: Revenue, 2018-2020, \$ bn
- Table 69. Novartis International AG: Company Snapshot
- Table 70. Novartis International AG: Business Segmentation
- Table 71. Novartis International AG: Revenue, 2017-2019, \$ bn
- Table 72. Novo Nordisk: Company Snapshot
- Table 73. Novo Nordisk: Product Portfolio
- Table 74. Patheon Inc.: Company Snapshot
- Table 75. Patheon Inc.: Business Segmentation in 2018
- Table 76. Patheon Inc.: Product Portfolio
- Table 77. Patheon Inc.: Revenue, 2017-2019, \$ billion
- Table 78. Patheon Inc.: Revenue by Region in 2018
- Table 79. Patheon Inc.: Recent Developments
- Table 80. Pfizer CentreSource: Company Snapshot
- Table 81. Pfizer CentreSource: Business Segmentation in 2018
- Table 82. Pfizer CentreSource: Product Portfolio
- Table 83. Pfizer CentreSource: Revenue, 2017-2019, \$ billion
- Table 84. Pfizer CentreSource: Revenue by Region in 2018
- Table 85. Hospira, Inc. (a subsidiary of Pfizer): Company Snapshot
- Table 86. Pfizer CentreSource: Recent Developments
- Table 87. Sanofi: Company Snapshot
- Table 88. Sanofi: Business Segmentation

Table 89. Sanofi: Revenue, 2018-2020, \$ bn

Table 90. Takeda Pharmaceutical Co. Ltd.: Company Snapshot

List Of Figures

LIST OF FIGURES

Figure 1. Research Method Flow Chart

Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation

Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2022-2032

Figure 4. Asia Pacific Pharmaceutical Manufacturing Industry, 2022-2032, \$ mn

Figure 5. World Healthcare Services Production, annual percentage change

Figure 6. Impact of COVID-19 on Business

Figure 7. Primary Drivers and Impact Factors of Asia Pacific Pharmaceutical Manufacturing Industry

Figure 8. Trends in the Approval of Cancer Therapies by FDA in the Twenty-First Century

Figure 9. Leading Causes of Death in the World, 2000 and 2019, million

Figure 10. Worldwide Geriatric Population (60 years and above) by Region, 2015 & 2030, million

Figure 11. World Population 65 and Over, % of Total Population, 1950-2060

Figure 12. Primary Restraints and Impact Factors of Asia Pacific Pharmaceutical Manufacturing Industry

Figure 13. Investment Opportunity Analysis

Figure 14. Porter's Five Forces Analysis of Asia Pacific Pharmaceutical Manufacturing Industry

Figure 15. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Formulation, 2022-2032, % of Revenue

Figure 16. Asia Pacific Addressable Market Cap in 2023-2032 by Formulation, Value (\$ mn) and Share (%)

Figure 17. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Tablets, 2022-2032, \$ mn

Figure 18. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Capsules, 2022-2032, \$ mn

Figure 19. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Injectable, 2022-2032, \$ mn

Figure 20. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Sprays, 2022-2032, \$ mn

Figure 21. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Suspensions, 2022-2032, \$ mn

Figure 22. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation:

Powders, 2022-2032, \$ mn

Figure 23. Asia Pacific Pharmaceutical Manufacturing Industry by Formulation: Other Formulations, 2022-2032, \$ mn

Figure 24. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration, 2022-2032, % of Sales Revenue

Figure 25. Asia Pacific Addressable Market Cap in 2023-2032 by Route of Administration, Value (\$ mn) and Share (%)

Figure 26. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration: Oral Medicine, 2022-2032, \$ mn

Figure 27. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration: Topical Medicine, 2022-2032, \$ mn

Figure 28. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration: Parenteral Medicine, 2022-2032, \$ mn

Figure 29. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration: Inhalations, 2022-2032, \$ mn

Figure 30. Asia Pacific Pharmaceutical Manufacturing Industry by Route of Administration: Other Routes of Administration, 2022-2032, \$ mn

Figure 31. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Consumer Group, 2022-2032, % of Sales Revenue

Figure 32. Asia Pacific Addressable Market Cap in 2023-2032 by Consumer Group, Value (\$ mn) and Share (%)

Figure 33. Asia Pacific Pharmaceutical Manufacturing Industry by Consumer Group: Children & Adolescents (17 years old and below), 2022-2032, \$ mn

Figure 34. Asia Pacific Pharmaceutical Manufacturing Industry by Consumer Group: Adults (18-64 years old), 2022-2032, \$ mn

Figure 35. Asia Pacific Pharmaceutical Manufacturing Industry by Consumer Group: Geriatric (65 years old and above), 2022-2032, \$ mn

Figure 36. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application, 2022-2032, % of Revenue

Figure 37. Asia Pacific Addressable Market Cap in 2023-2032 by Therapeutic Application, Value (\$ mn) and Share (%)

Figure 38. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Cardiovascular Diseases, 2022-2032, \$ mn

Figure 39. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Pain, 2022-2032, \$ mn

Figure 40. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Diabetes, 2022-2032, \$ mn

Figure 41. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Cancer, 2022-2032, \$ mn

- Figure 42. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Respiratory Diseases, 2022-2032, \$ mn
- Figure 43. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Neurological Diseases, 2022-2032, \$ mn
- Figure 44. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Orthopedics, 2022-2032, \$ mn
- Figure 45. Asia Pacific Pharmaceutical Manufacturing Industry by Therapeutic Application: Other Applications, 2022-2032, \$ mn
- Figure 46. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type, 2022-2032, % of Revenue
- Figure 47. Asia Pacific Addressable Market Cap in 2023-2032 by Drug Type, Value (\$ mn) and Share (%)
- Figure 48. Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type: Branded Prescription Drugs, 2022-2032, \$ mn
- Figure 49. Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type: Generic Prescription Drugs, 2022-2032, \$ mn
- Figure 50. Asia Pacific Pharmaceutical Manufacturing Industry by Drug Type: OTC Drugs, 2022-2032, \$ mn
- Figure 51. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Distribution Channel, 2022-2032, % of Revenue
- Figure 52. Asia Pacific Addressable Market Cap in 2023-2032 by Distribution Channel, Value (\$ mn) and Share (%)
- Figure 53. Asia Pacific Pharmaceutical Manufacturing Industry by Distribution Channel: Retail Channels, 2022-2032, \$ mn
- Figure 54. Asia Pacific Pharmaceutical Manufacturing Industry by Distribution Channel: Non-retail Channels, 2022-2032, \$ mn
- Figure 55. Breakdown of Asia Pacific Pharmaceutical Manufacturing Industry by Manufacturing Facility, 2022-2032, % of Revenue
- Figure 56. Asia Pacific Addressable Market Cap in 2023-2032 by Manufacturing Facility, Value (\$ mn) and Share (%)
- Figure 57. Asia Pacific Pharmaceutical Manufacturing Industry by Manufacturing Facility: In-house Facility, 2022-2032, \$ mn
- Figure 58. Asia Pacific Pharmaceutical Manufacturing Industry by Manufacturing Facility: Outsourced Facility, 2022-2032, \$ mn
- Figure 59. Asia-Pacific Pharmaceutical Manufacturing Industry, 2022-2032, \$ mn
- Figure 60. Breakdown of APAC Pharmaceutical Manufacturing Industry by Country, 2022 and 2032, % of Revenue
- Figure 61. Contribution to APAC 2023-2032 Cumulative Market by Country, Value (\$ mn) and Share (%)

- Figure 62. Pharmaceutical Manufacturing Industry in Japan, 2022-2032, \$ mn
- Figure 63. Pharmaceutical Manufacturing Industry in China, 2022-2032, \$ mn
- Figure 64. Pharmaceutical Manufacturing Industry in Australia, 2022-2032, \$ mn
- Figure 65. Pharmaceutical Manufacturing Industry in India, 2022-2032, \$ mn
- Figure 66. Pharmaceutical Manufacturing Industry in South Korea, 2022-2032, \$ mn
- Figure 67. Pharmaceutical Manufacturing Industry in Rest of APAC, 2022-2032, \$ mn
- Figure 68. Growth Stage of Asia Pacific 3D Printing Industry over the Forecast Period
- Figure 69. Top products of AstraZeneca based on revenue from 2016 to 2019 (in million U.S. dollars)

I would like to order

Product name: Asia Pacific Pharmaceutical Manufacturing Industry 2022-2032 by Formulation, Route of Administration, Consumer Group, Therapeutic Application, Drug Type, Distribution Channel, Manufacturing Facility, and Country: Trend Forecast and Growth Opportunity

Product link: <https://marketpublishers.com/r/A698267F4955EN.html>

Price: US\$ 2,210.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A698267F4955EN.html>